Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
Type:
Grant
Filed:
February 25, 2015
Date of Patent:
February 12, 2019
Assignee:
ACUCELA INC.
Inventors:
Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Anna Gall, Mark W. Orme, Jennifer Gage, Thomas L. Little, Jr., Qin Jiang, Lana Michele Rossiter, Kevin F. McGee, Jr., Ryo Kubota
Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
Type:
Grant
Filed:
September 26, 2014
Date of Patent:
February 5, 2019
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
Abstract: This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
Abstract: Provided here are nitric oxide-releasing compounds that include at least two different NO donor functional groups of the same class. In some embodiments, such nitric oxide-releasing compounds are macromolecules such as dendrimer and co-condensed silica. Pharmaceutical compositions, wound dressings, kits and methods of treatments are also provided herein.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
February 5, 2019
Assignees:
The University of North Carolina at Chapel Hill, Novan, Inc.
Inventors:
Mark Schoenfisch, Yuan Lu, Nathan Stasko, Jian Bao
Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
Type:
Grant
Filed:
February 23, 2017
Date of Patent:
January 22, 2019
Assignee:
Board of Regents of The University of Texas System
Inventors:
Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander, Jeffrey M. Zigman
Abstract: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.
Type:
Grant
Filed:
January 15, 2016
Date of Patent:
January 8, 2019
Assignee:
Board of Regents of The University of Texas System
Inventors:
Steven L. McKnight, Joseph M. Ready, Andrew A. Pieper, Jef K. De Brabander
Abstract: Compounds of formula (II): wherein R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
Type:
Grant
Filed:
August 14, 2017
Date of Patent:
January 8, 2019
Assignee:
Aquinox Pharmaceuticals (Canada) Inc.
Inventors:
Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
December 18, 2018
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Scott D. Kuduk, Nigel Liverton, Yunfu Luo
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
Type:
Grant
Filed:
October 25, 2017
Date of Patent:
December 18, 2018
Assignees:
ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
Inventors:
Ramin Faghih, Achim Moeller, Michael Ochse, Frauke Pohlki, Martin Schmidt, Kevin Sippy, Sean Turner, Elizabeth Louise Van Der Kam
Abstract: In various aspects, the present disclosure provides methods, compositions, reactions mixtures, kits, and systems for sequencing both RNA and DNA from a single source sample. In some embodiments, RNA is treated so as to differentiate RNA sequences from DNA sequences derived from the same sample. In some embodiments, the RNA and DNA are cell-free polynucleotides.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
December 4, 2018
Assignee:
GRAIL, Inc.
Inventors:
Matthew Larson, H. John Kim, Nick Eattock, Arash Jamshidi
Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Abstract: Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.
Abstract: Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents —C(CH3), A represents unsubstituted or substituted 5-, 6- or 10-membered aryl or heteroaryl, n is 0 or 1 and B is a bicyclic heteromoiety defined in the specification. Compounds are phosphodiesterase 10A inhibitors and can find use in medicine in the treatment psychotic, neurological and cognitive functions diseases and disorders.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
November 27, 2018
Assignee:
CELON PHARMA S.A.
Inventors:
Rafal Moszczynski-Petkowski, Lukasz Bojarski, Maciej Wieczorek, Jakub Majer, Sylwia Janowska, Mikolaj Matloka, Malgorzata Borkowska, Filip Stefaniak, Monika Lamparska-Przybysz, Krzysztof Dubiel
Abstract: The present application relates to novel bicyclic compounds, to compositions comprising these compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.
Type:
Grant
Filed:
December 1, 2015
Date of Patent:
November 20, 2018
Assignee:
BAYER CROPSCIENCE AKTIENGESELLSCHAFT
Inventors:
Peter Jeschke, Alexander Arlt, Silvia Cerezo-Galvez, Arnd Voerste, Martin Füßlein, Reiner Fischer, Thomas Bretschneider, Kerstin Ilg, Olga Malsam, Peter Lösel
Abstract: The present invention relates to compositions and methods for controlling glycemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies for diabetes and related disorders, based on compositions controlling the blood glucose level.
Type:
Grant
Filed:
April 29, 2015
Date of Patent:
October 9, 2018
Assignee:
PHARNEXT
Inventors:
Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Rodolphe Hajj
Abstract: A tetrazolinone compound represented by formula (1): Wherein E represents a 5-membered aromatic heterocyclic group such as a pyrazolyl group, a thiazolyl group, or an imidazolyl group; R4 and R5 represent a hydrogen atom; R6 represents an alkyl group having 1-12 carbon atoms; R7, R8, and R9 represent a hydrogen atom; R10 represents an alkyl group having 1-3 carbon atoms, or a haloalkyl group having 1-3 carbon atoms; Y represents an oxygen atom; and Q represents an oxygen atom, has excellent control activity against pests.